Anavex Life Sciences Corp.

NASDAQ:AVXL

Biotechnology

Healthcare
$0.72 -1.67%

-$0.04 today

Market cap
$66.69M
Beta
1.12
P/E (TTM)
-5.9
EPS (TTM)
-$0.45
52W Low $2.41High $13.99

Volume 1.06M

Average 1.39M

AVXL Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Anavex Life Sciences Corp.NASDAQ: AVXL

Operating Expenses · Q1 FY2026 · quarter ended Dec 2025

Operating expenses declines year over year

Q1 FY2026 operating expenses of $6.78M fell 50.1% year over year, behind the -19.1% change in trailing-twelve-month operating expenses. Sequentially, it fell 37.5% from the prior quarter. Over 3 fiscal years it compounded at +0.3% a year.

Context

  • Operating expenses increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -50.1% toward the trailing-twelve-month pace of -19.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterDec 2025
$6.78M-37.5% QoQ
Last fiscal yearSep 2025
$51.41M-2.8% YoY
LTMDec 2025
$44.6M-19.1% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-50.1%——
1 year-2.8%——
3-year CAGR+0.3%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
51.41M USD
Year-over-year change
-2.8%
4-year CAGR
+5.2%

Operating Expenses vs competitors

How AVXL compares with its peers on the latest reported figures

  • Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -19.1% is the 9th highest of 10, against a peer median of +5.9%.
  • Over three fiscal years its annual growth of +0.3% compares with a peer median of -0.3%.
AVXL Competitors
Operating Expenses for AVXL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ARVNArvinas, Inc.LTM Mar 2026$336.8M USD-35.3%-1.9%376.7%
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$265.04M USD+55.2%+55.0%—
RGNXREGENXBIO Inc.LTM Mar 2026$256.57M USD-7.5%-1.0%292.1%
MGTXMeiraGTx Holdings plcLTM Mar 2026$178.28M USD+5.9%+11.3%223.5%
ERASErasca, Inc.LTM Sep 2026$176.19M USD+23.1%-19.4%—
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$160.33M USD+76.4%+57.4%—
VALNValneva SELTM Mar 2026€145.42M EUR-1.4%-0.3%93.0%
ABSIAbsci CorporationLTM Mar 2026$104.36M USD+58.2%+29.3%5683.9%
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$99.95M USD-10.4%-13.9%281.2%
AVXLAnavex Life Sciences Corp.LTM Dec 2025$44.6M USD-19.1%+0.3%—
Peer median (excluding AVXL) —+5.9%-0.3%286.7%

Competitors are the stored peer set for AVXL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development32.98M37.92M43.72M41.84M37.59M
Selling, General & Admin9.02M13.07M12.05M11.04M13.82M
Operating Expenses42M50.99M55.76M52.88M51.41M
Depreciation & Amortization00000
EBITDA(37.64M)(47.62M)(46.54M)(43M)(46.38M)
EBITDA Margin—————
Operating Income(42M)(50.99M)(55.76M)(52.88M)(51.41M)
Operating Margin—————
Interest Income26K947K6.52M7.32M4.68M
Interest Expense00964K00
Other Income / Expenses4.36M3.37M8.26M9.88M5.03M
Income Before Tax(37.64M)(47.62M)(47.51M)(43M)(46.38M)
Pre-Tax Margin—————
Income Tax Expense268K358K000
Net Income(37.91M)(47.98M)(47.51M)(43M)(46.38M)
Net Margin—————
EPS (Basic)(0.54)(0.62)(0.60)(0.52)(0.54)
EPS (Diluted)(0.54)(0.62)(0.60)(0.52)(0.54)
Weighted Avg Shares69.8M76.91M79.79M83.47M85.29M
Weighted Avg Shares (Diluted)69.8M76.91M79.79M83.47M85.29M

Anavex Life Sciences Corp.

NASDAQ:AVXL

Intrinsic Alpha fair value

Locked

Current Price

$0.72

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.